Understanding HER2 Testing in BTC: Detection and Clinical Approaches

Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.

EP: 1.Guiding Patients Through Advanced BTC Prognosis and Expectations

EP: 2.The Importance of Early Biomarker Testing in Managing Advanced BTC

EP: 3.Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP: 4.Expert Insights: Challenges With ctDNA Testing in BTC

EP: 5.Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP: 6.Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

Now Viewing

EP: 7.Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP: 8.Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

• Switching gears to BTC patients with disease progression requiring subsequent therapy, do you reperform biomarker testing at disease progression?
• How prevalent is HER2 amplification in BTC? How can HER2 amplification be detected and which techniques are you utilizing in your clinical practice (IHC, FISH, or NGS)?
• Please comment on any other important nuances to HER2 testing.

Related Videos